Highlights The use of menopausal hormone therapy by breast cancer survivors is controversial. Non-hormonal therapies are the first-line option but may not adequately control symptoms. Low-dose vaginal estrogen appears effective with minimal systemic absorption. The use of systemic menopausal hormone therapy remains debated due to heterogeneous and limited safety data. Management should be individualized, with multidisciplinary shared decision-making.
Granat et al. (Sun,) studied this question.